Low PE pharma penny stock below Rs 60: Company reports revenue of Rs 70.74 crore and profit of Rs 0.29 crore!

Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical company that focuses on the production, stocking, selling, and supply of both branded and generic medicines. With a substantial portfolio of 610 pharmaceutical product registrations, Balaxi offers a diverse range of products, including tablets, injectables, liquids, and capsules, sourced from WHO-GMP-certified contract manufacturers located in India, China and Portugal.

According to Quarterly Results, the net sales increased by 8 per cent to Rs 70.74 crore in Q1FY26 compared to Q1FY25. The company reported a net profit of Rs 0.29 crore in Q1FY26. In its annual results (FY25), the net sales increased by 22 per cent to Rs 293 crore compared to FY24. The company reported a net profit of Rs 25 crore in FY25 compared to a net loss of Rs 2 crore in FY24, an increase of 1,350 per cent.

The Managing Director updated the Board on the significant progress of the Company's first Pharmaceutical Formulation plant in Jadcherla, Hyderabad. All installation, operational, and performance qualifications for machinery are complete. Water validation and vendor qualification are currently underway, projected to finish by August 2025. With the manufacturing test license already secured, the plant anticipates commencing stability batch production in early September 2025, marking a crucial step towards full operation.

The shares of the company have a PE of 14x whereas the industry PE is 34x. The company has a market cap of over Rs 250 crore and the stock is up by 4 per cent from its 52-week low of Rs 46.19 per share.

Disclaimer: The article is for informational purposes only and not investment advice.